Therapy Detail

Therapy Name Adavosertib + PF-00477736
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Adavosertib MK-1775|AZD1775|AZ1775 WEE1 Inhibitor 2 Adavosertib (MK-1775) is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity (PMID: 22084170).
PF-00477736 PF-477736 CHK1 Inhibitor 14 PF-00477736 is an ATP-competitive inhibitor of Chk1, which potentially increases sensitivity to chemotherapeutic agents, resulting in decreased tumor growth (PMID: 18723486).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 wild-type colon cancer sensitive Adavosertib + PF-00477736 Preclinical Actionable In a preclinical study, MK-1775, in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237). 22713237
Clinical Trial Phase Therapies Title Recruitment Status